carbamates has been researched along with Viremia in 19 studies
Viremia: The presence of viruses in the blood.
Excerpt | Relevance | Reference |
---|---|---|
"Owing to the advent of pangenotypic direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) treatment, utilization of HCV-infected deceased donor kidneys with simplified genotyping/subtyping-free sofosbuvir/velpatasvir (SOF/VEL) treatment strategy is now becoming a promising strategy for expanding the organ donor pool." | 4.12 | Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. ( Dai, H; Fang, C; Guo, Y; Hu, S; Lan, G; Liu, Q; Nie, M; Peng, F; Peng, L; Tan, L; Xie, X; Zhang, H; Zhong, M, 2022) |
"Amprenavir (APV) is an HIV protease inhibitor (PI) used for the treatment of either naive or PI-experienced HIV-infected patients." | 3.72 | Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. ( Affolabi, D; Bossi, P; Bricaire, F; Calvez, V; Costagliola, D; Delaugerre, C; Katlama, C; Ktorza, N; Lamotte, C; Marcelin, AG; Mohand, HA; Peytavin, G; Voujon, D; Wirden, M, 2004) |
" Adverse events (AEs) associated with the study medication occurred in 21% of patients." | 2.74 | Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. ( Luque, I; Mallolas, J; Pérez-Elias, MJ; Rodríguez-Alcántara, F; Sánchez-Conde, M; Soriano, V, 2009) |
" The most common adverse events considered to be possibly drug related were nausea, rash, oral paresthesia, diarrhea, and fatigue." | 2.69 | A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. ( Antunes, F; Brown, DJ; Clumeck, N; Fetter, A; Haubrich, R; Kahl, L; Lang, W; Pagano, G; Richman, D; Schooley, R; Sereni, D; Stein, A; Thompson, M; van der Ende, ME, 1999) |
" Importantly, adjustments to the immunosuppressant dosage were not required." | 1.42 | Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. ( Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (10.53) | 18.2507 |
2000's | 8 (42.11) | 29.6817 |
2010's | 6 (31.58) | 24.3611 |
2020's | 3 (15.79) | 2.80 |
Authors | Studies |
---|---|
Zhang, H | 1 |
Liu, Q | 1 |
Hu, S | 1 |
Zhong, M | 1 |
Peng, F | 1 |
Guo, Y | 1 |
Fang, C | 1 |
Nie, M | 1 |
Tan, L | 1 |
Dai, H | 1 |
Xie, X | 1 |
Peng, L | 1 |
Lan, G | 1 |
Terrault, NA | 1 |
Burton, J | 1 |
Ghobrial, M | 1 |
Verna, E | 1 |
Bayer, J | 1 |
Klein, C | 1 |
Victor, D | 1 |
Mohan, S | 1 |
Trotter, J | 1 |
Dodge, J | 1 |
Niemann, CU | 1 |
Rubin, RA | 1 |
Yu, ML | 1 |
Huang, CF | 1 |
Wei, YJ | 1 |
Lin, WY | 1 |
Lin, YH | 1 |
Hsu, PY | 1 |
Hsu, CT | 1 |
Liu, TW | 1 |
Lee, JJ | 1 |
Niu, SW | 1 |
Huang, JC | 1 |
Hung, TS | 1 |
Yeh, ML | 1 |
Huang, CI | 1 |
Liang, PC | 1 |
Hsieh, MY | 1 |
Chen, SC | 1 |
Huang, JF | 1 |
Chang, JM | 1 |
Chiu, YW | 1 |
Dai, CY | 1 |
Hwang, SJ | 1 |
Chuang, WL | 1 |
Antón, MD | 1 |
Polanco, A | 1 |
Ferrando, I | 1 |
Latorre, P | 1 |
Pascual, A | 1 |
Moreno Osset, E | 1 |
Gottlieb, RL | 1 |
Sam, T | 1 |
Wada, SY | 1 |
Trotter, JF | 1 |
Asrani, SK | 1 |
Lima, B | 1 |
Joseph, SM | 1 |
Gonzalez-Stawinski, GV | 1 |
Hall, SA | 1 |
Teraoka, Y | 1 |
Uchida, T | 1 |
Imamura, M | 1 |
Hiraga, N | 1 |
Osawa, M | 1 |
Kan, H | 1 |
Saito, Y | 1 |
Tsuge, M | 1 |
Abe-Chayama, H | 1 |
Hayes, CN | 1 |
Makokha, GN | 1 |
Aikata, H | 1 |
Miki, D | 1 |
Ochi, H | 1 |
Ishida, Y | 1 |
Tateno, C | 1 |
Chayama, K | 1 |
Duerr, M | 1 |
Schrezenmeier, EV | 1 |
Lehner, LJ | 1 |
Bergfeld, L | 1 |
Glander, P | 1 |
Marticorena Garcia, SR | 1 |
Althoff, CE | 1 |
Sack, I | 1 |
Brakemeier, S | 1 |
Eckardt, KU | 1 |
Budde, K | 1 |
Halleck, F | 1 |
Herzer, K | 1 |
Papadopoulos-Köhn, A | 1 |
Walker, A | 1 |
Achterfeld, A | 1 |
Paul, A | 1 |
Canbay, A | 1 |
Timm, J | 1 |
Gerken, G | 1 |
Sankawa, Y | 1 |
Pérez-Elias, MJ | 1 |
Sánchez-Conde, M | 1 |
Soriano, V | 1 |
Mallolas, J | 1 |
Luque, I | 1 |
Rodríguez-Alcántara, F | 1 |
Paulsen, D | 1 |
Liao, Q | 1 |
Fusco, G | 1 |
St Clair, M | 1 |
Shaefer, M | 1 |
Ross, L | 1 |
Bogner, JR | 1 |
Eberle, J | 1 |
Troendle, U | 1 |
Goebel, FD | 1 |
Marcelin, AG | 1 |
Affolabi, D | 1 |
Lamotte, C | 1 |
Mohand, HA | 1 |
Delaugerre, C | 1 |
Wirden, M | 1 |
Voujon, D | 1 |
Bossi, P | 1 |
Ktorza, N | 1 |
Bricaire, F | 1 |
Costagliola, D | 1 |
Katlama, C | 1 |
Peytavin, G | 1 |
Calvez, V | 1 |
Khanlou, H | 1 |
Bhatti, L | 1 |
Farthing, C | 1 |
Haubrich, R | 1 |
Thompson, M | 1 |
Schooley, R | 1 |
Lang, W | 1 |
Stein, A | 1 |
Sereni, D | 1 |
van der Ende, ME | 1 |
Antunes, F | 1 |
Richman, D | 1 |
Pagano, G | 1 |
Kahl, L | 1 |
Fetter, A | 1 |
Brown, DJ | 1 |
Clumeck, N | 1 |
Rizzardi, GP | 1 |
De Boer, RJ | 1 |
Hoover, S | 1 |
Tambussi, G | 1 |
Chapuis, A | 1 |
Halkic, N | 1 |
Bart, PA | 1 |
Miller, V | 1 |
Staszewski, S | 1 |
Notermans, DW | 1 |
Perrin, L | 3 |
Fox, CH | 1 |
Lange, JM | 1 |
Lazzarin, A | 1 |
Pantaleo, G | 1 |
Chang, HE | 1 |
Tilling, R | 1 |
Kinloch, S | 1 |
Goh, LE | 1 |
Cooper, D | 1 |
Lampe, F | 1 |
Zaunders, J | 1 |
Hoen, B | 1 |
Tsoukas, C | 1 |
Andersson, J | 1 |
Janossy, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Micro-elimination of Hepatitis C Virus Infection With Pan-genotypic DAA Regimen in Hepatitis C Highly Endemic and Contagious Community (ERASE-C)[NCT03891550] | Phase 3 | 135 participants (Anticipated) | Interventional | 2019-05-13 | Active, not recruiting | ||
Comprehensive Surveillance of HCV Infecion in Uremics Under Maintenance Hemodialysis and Linking to Medical Care in Taiwan[NCT03803410] | 2,973 participants (Actual) | Observational | 2019-01-07 | Completed | |||
A Phase II Trial to Evaluate the Safety and Efficacy of Induction Treatment With Lamivudine Plus Stavudine Plus Abacavir Plus Amprenavir/Ritonavir Followed by Supervised Treatment Interruption in Subjects With Acute HIV Infection or Recent Seroconversion[NCT00000940] | Phase 2 | 121 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
6 trials available for carbamates and Viremia
Article | Year |
---|---|
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbam | 2019 |
[Complication sequelae prevented, morbidity decreased].
Topics: Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Py | 2015 |
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Topics: Adult; Carbamates; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Fever; Fura | 2009 |
Amprenavir in pre-treated patients: virological and immunological response in a cohort of 45 patients.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination | 2003 |
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protea | 1999 |
Therapeutic vaccination in primary HIV infection, the Quest trial.
Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Ly | 2002 |
13 other studies available for carbamates and Viremia
Article | Year |
---|---|
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chroni | 2022 |
Prospective Multicenter Study of Early Antiviral Therapy in Liver and Kidney Transplant Recipients of HCV-Viremic Donors.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C; Hetero | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C).
Topics: Antiviral Agents; Carbamates; Drug Combinations; Hemodialysis Units, Hospital; Hepatitis C; Heterocy | 2021 |
Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals.
Topics: Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Guani | 2018 |
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse.
Topics: Adult; Antiviral Agents; Carbamates; Drug Combinations; Female; Heart Failure; Heart Transplantation | 2017 |
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Topics: Animals; Antiviral Agents; Benzazepines; Biomarkers; Carbamates; Drug Combinations; Drug Resistance, | 2018 |
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus | 2015 |
Genotypic and phenotypic cross-resistance patterns to lopinavir and amprenavir in protease inhibitor-experienced patients with HIV viremia.
Topics: Carbamates; Cross-Sectional Studies; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV P | 2002 |
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Topics: Adult; Amino Acid Substitution; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Femal | 2004 |
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Adminis | 2006 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies | 2000 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Inf | 1995 |
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates; | 2002 |